Oral SERDs in ER+/HER2- metastatic breast cancer, an analysis of ESR1 wild type/mutant subgroups
An individual patient data metanalysis suggests that oral SERDs improve progression-free survival in ESR1 mutant subgroup, with no significant benefit in ESR1 wild type patients